Anti-obesity Pharmacotherapy and Inflammation

NCT05756764 · Active, not recruiting

Last updated 2026-05-28

This clinical trial tests a medication to help people with obesity lose weight by reducing inflammation in the body.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 30 people Planned (estimated).

Who can join Ages 35–60 · all sexes

Timeline Started 2023-06 · est. completion 2026-02

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT05756764 ↗

Description as written by the study sponsor.

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Treatments tested

Semaglutide also known as Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy Drug

Medication for weight loss
Phentermine-Topiramate combination also known as Qsymia Drug

Medication for weight loss
Phentermine also known as Lomaira, Adipex-P Drug

Medication for weight loss
Tirzepatide also known as Mounjaro, Zepbound, GIP/GLP-1 RA Drug

Medication for weight loss
Topiramate also known as Topamax, Trokendi XR, Qudexy XR Drug

Medication for weight loss
Diethylpropion also known as Tenuate, Diethylcathinone Drug

Medication for weight loss
Naltrexone/Bupropion also known as Contrave Drug

Medication for weight loss
Liraglutide also known as Saxenda, Victoza, Glucagon-like peptide-1 receptor (GLP1-R) agonist Drug

Medication for weight loss

Main thing measured	weight loss
Sponsor	Louisiana State University Health Sciences Center in New Orleans
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05756764 ↗